Manufacturing mesenchymal stromal cells in a microcarrier-microbioreactor platform can enhance cell yield and quality attributes: case study for acute respiratory distress syndrome.

导出 OA

翻译打印收藏纠错

作者： Brandon,Krupczak ^[1] ; Camille,Farruggio ^[2] ; Krystyn J,Van Vliet ^[3]

作者单位： Harvard-MIT Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, Massachusetts, 02139, USA. ^[1] Singapore-MIT Alliance for Research and Technology, Critical Analytics for Manufacturing Personalised-medicine, 1 Create Way, Singapore, 138602, Singapore. ^[2] Department of Materials Science and Engineering, Massachusetts Institute of Technology, 77 Massachusetts Avenue, Cambridge, 02139, USA. ^[3] Department of Materials Science and Engineering, Massachusetts Institute of Technology, 77 Massachusetts Avenue, Cambridge, 02139, USA. krystyn.vv@cornell.edu. ^[4] Department of Biological Engineering, Massachusetts Institute of Technology, 77 Massachusetts Avenue, Cambridge, MA, 02139, USA. krystyn.vv@cornell.edu. ^[5] Singapore-MIT Alliance for Research and Technology, Critical Analytics for Manufacturing Personalised-medicine, 1 Create Way, Singapore, 138602, Singapore. krystyn.vv@cornell.edu. ^[6] Departments of Materials Science & Engineering and Biomedical Engineering, Cornell University, 144 Feeney Way, Ithaca, NY, 14853, USA. krystyn.vv@cornell.edu. ^[7]